首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

南美洲和中美洲T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體腫瘤）腫瘤）

市場調查報告書

商品編碼

1452637

南美洲和中美洲T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體腫瘤）腫瘤）

South & Central America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 55 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年南美洲和中美洲T細胞治療市場價值為8,411萬美元，預計到2030年將達到2.6559億美元；預計2022年至2030年CAGR為15.5%。

T 細胞治療批准數量的增加推動了南美洲和中美洲 T 細胞治療市場

標靶治療、更快、更有效的恢復以及減少副作用都是 T 細胞療法的優點。在全球範圍內，細胞療法由於獲得了各種批准而被廣泛採用：

2023 年：吉利德旗下 Kite 公司宣佈在沙烏地阿拉伯、新加坡和巴西開展業務，作為其商業擴張的一部分。 Kite 已在這三個國家提交了其 CAR T 細胞治療產品的監管申請。

例如，2022年6月，百時美施貴寶的Breyanzi (lisocabtagene maraleucel) 獲得FDA 批准，這是一種CD19 定向嵌合抗原受體(CAR) T 細胞療法，用於治療成人大B 細胞淋巴瘤(LBCL ) 患者。

2022年2月，美國食品藥物管理局(FDA) 批准Yescarta (axicabtagene ciloleucel) CAR T 細胞療法用於治療一線化學免疫療法難治或一線化學免疫療法12 個月內復發的大B 細胞淋巴瘤成人患者。 Yescarta 是第一個獲得全國綜合癌症網路 (NCCN) 1 類推薦的 CAR T 細胞療法。

2022年2月，FDA核准了ciltacabtagene autoleucel（商品名CARVYKTI）用於治療經過四線或四線以上治療（包括蛋白酶體抑制劑、免疫調節劑和抗CD38單株抗體）後復發或難治性多發性骨髓瘤的成年患者。

2022年1月，FDA核准Kimmtrak（tebentafusp-tebn）用於治療HLA-A*02:01陽性的不可切除或轉移性葡萄膜黑色素瘤患者。

2021年3月，Abecma（idecabtagene vicleucel）被FDA核准用於治療復發或難治性多發性骨髓瘤。該療法是一種針對 B 細胞成熟抗原 (BCMA) 的基因改造自體 T 細胞免疫療法，適用於治療患有難治性多發性骨髓瘤的成年患者。

因此，越來越多的 T 細胞療法獲批正在推動市場成長。

南美洲和中美洲 T 細胞治療市場概述

南美洲和中美洲 T 細胞治療市場僅限於巴西，因為該產品僅在該國獲得批准和商業化。根據《巴西癌症學雜誌》報道，預計 2023 年至 2025 年期間將新增約 704,000 例癌症病例。據估計，巴西每年診斷出超過 12,000 例非何杰金氏淋巴瘤 (NHL) 病例。巴西衛生監管機構(ANVISA) 已在巴西批准了兩種CAR T 細胞療法：tisagenlecleucel（諾華公司），用於治療患有RR B 細胞急性淋巴細胞白血病(ALL) 的兒科患者和年輕人以及患有復發/難治性(RR) 的成人患者瀰漫性大 B 細胞淋巴瘤和 ciltacabtagene autoleucel (cilta-cel) 用於治療復發/難治性多發性骨髓瘤 (RRMM) 患者。此外，2022年8月，吉利德旗下公司Kite透過在巴西、新加坡和沙烏地阿拉伯開展業務來擴大業務。 Kite 已提交其 CAR T 細胞治療產品的監管申請。癌症和淋巴瘤病例的增加以及 T 細胞療法的應用和臨床試驗數量的增加預計將在未來幾年推動需求。

南美洲和中美洲 T 細胞治療市場收入及 2030 年預測（百萬美元）

南美洲和中美洲 T 細胞治療市場細分

南美洲和中美洲 T 細胞治療市場分為模式、治療類型、適應症和國家。

根據模式，南美洲和中美洲 T 細胞治療市場分為研究和商業化市場。 2022年，商業化細分市場將佔據更大的市場佔有率。

根據治療類型，南美洲和中美洲T細胞治療市場分為CAR T細胞療法和T細胞受體（TCR）療法。 2022年，CAR T細胞療法領域將佔據更大的市場佔有率。

根據適應症，南美洲和中美洲 T 細胞治療市場分為血液惡性腫瘤和實體腫瘤。 2022 年，血液惡性腫瘤細分市場佔據最大市場。

從國家來看，南美洲和中美洲 T 細胞治療市場僅限於巴西。 2022 年，巴西在南美洲和中美洲 T 細胞治療市場佔有率中佔據主導地位。

百時美施貴寶公司、吉利德科學公司、楊森全球服務有限責任公司和諾華公司是南美洲和中美洲 T 細胞治療市場的一些領導公司。

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America T Cell Therapy Market Segmentation

The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - South & Central America Market Analysis

5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America T Cell Therapy Market - Country Analysis

9.1 Overview
- 9.1.1 South & Central America T Cell Therapy Market by Country
  - 9.1.1.1 Brazil
    - 9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Janssen Global Services LLC
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Gilead Sciences Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Bristol-Myers Squibb Co
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Novartis AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. South & Central America T Cell Therapy Market Segmentation 8
Table 2. South & Central America T Cell Therapy Market , by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. Brazil: South & Central America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil: South & Central America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil: South & Central America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Recent Organic Growth Strategies in South & Central America T Cell Therapy Market
Table 8. Recent Inorganic Growth Strategies in the South & Central America T Cell Therapy Market
Table 9. Glossary of Terms, South & Central America T Cell Therapy Market

List Of Figures

Figure 1. South & Central America T Cell Therapy Market Segmentation, By Country 9
Figure 2. South & Central America T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. South & Central America T Cell Therapy Market , By Key Countries, 2022 and 2030 (%)
Figure 16. Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Growth Strategies in T Cell Therapy Market